Ovarian Cancer

Topotecan with Avastin in ovarian cancer

Topotecan is an old drug that can be used in second line( after failure of the initial drugs) treatment of ovarian cancer.  In ovarian cancer, topotecan has demonstrated activity in both platinum-and Taxol resistant tumors. In a randomized, phase III study, patients like this had similar response rates with topotecan or Taxol. That phase III study, and earlierphase II studies, established topotecan as an important treatment option for patients

Read more
Continuing Avastin past progression in ovarian cancer

Avastin first line of ovarian cancer is now generally accepted as a component of combination chemotherapy and is reviewed separately. The issue is. Should one continues Avastin into the next line of therapy after progression. For chemotherapy, if a drug failed in first line, it should not be continued in the second line (exceptions are when a long time had elapsed since the initial remission and the like). Unfortunately there is no literature specifically

Read more
First line Avastin for ovarian cancer

Avastin(Bevacizumab) is an effective drug for ovarian cancer but how to use it still being clarified. Particularly, the debate has been ongoing but its place in first-line treatment. Some answers and now available. At the 2010 American Society of Clinical Oncology Annual conference in Chicago, the Gynecologic Oncology Group(GOG) presented the results of the latest clinical trial for Avastin and ovarian cancer. GOG 218 (activated in October 2005)

Read more
Octreotide for Small Bowel Obstruction

Malignant bowel obstruction (MBO) is a common and very difficult problem to manage at the end of the course of ovarian cancer, Surgery can help but is not always possible and often only temporarily effective. It should not be undertaken in patients known to have poor prognostic criteria for surgical intervention such as intra-abdominal carcinomatosis, poor performance status and massive ascites. Nasogastric drainage should generally only be a temporary

Read more
OVA-1 Testing in Ovarian Cancer

OVA1 test is FDA cleared for women who meet the following criteria: (i) over age 18, (ii) ovarian mass present for which surgery is planned, and (iii) not yet referred to an oncologist. It is an aid to assess the likelihood that ovarian cancer is present when a physician is not sure. The test should not be used without a prior independent prior clinical/radiological evaluation and is not intended to be a screening test or to determine whether a patient

Read more
TACE for Liver Metastases from Ovarian Cancer

Transcatheter arterial chemoembolization (TACE) of the liver is an alternative to conventional systemic or intra-arterial chemotherapy, and to various nonsurgical tumor-killing techniques. It is meant to treat resectable and non-resectable tumors. The rationale for TACE is that infusions of viscous material containing one or more chemo drugs may have synergy: chemotherapy killing cancer cells that are already weakened from a lack of oxygen in the

Read more

Fatal error: Call to undefined function fw_blog_pagination() in /home/content/43/9379243/html/wp-content/themes/wisdom/blog_category.php on line 39